Literature DB >> 3167805

Intrapericardial instillation of platin in malignant pericardial effusion.

M V Fiorentino1, O Daniele, P Morandi, S M Aversa, C Ghiotto, A Paccagnella, A Fornasiero.   

Abstract

Six patients (four men and two women) affected by malignant pericardial effusion, as confirmed by cytologic examination, were treated with direct intrapericardial administration of cisplatin. Median age was 36.8 years (range, 18 to 56 years). After insertion of a radiopaque polyurethane catheter (Centracath Vygon, Laboratoires Pharmaceutiques, Vygon-Ecouen, France), fluid was drained and cisplatin (10 mg in 20 ml of normal saline) was instilled over 5 minutes on 5 consecutive days (total cisplatin dose, 50 mg). At the end of the course, the catheter was withdrawn. Courses were repeated every 2 or 3 weeks in case of fluid reaccumulation. The median number of courses was two, with a range of one to three courses. Three patients achieved complete response and all three died of primary disease progression without evidence of pericardial recurrence or stricture. Mild nausea occurred in all patients. No hematologic and renal toxicity and local or infectious complications were observed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3167805     DOI: 10.1002/1097-0142(19881101)62:9<1904::aid-cncr2820620906>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  New approaches to the management and treatment of malignant pericardial effusion.

Authors:  W Tomkowski; M Szturmowicz; A Fijałkowska; J Burakowski; S Filipecki
Journal:  Support Care Cancer       Date:  1997-01       Impact factor: 3.603

2.  Thoracoscopic pericardial fenestration: diagnostic and therapeutic aspects.

Authors:  A Cantó; R Guijarro; A Arnau; A Fernández-Centeno; M A Císcar; J Galbis; A García-Vilanova
Journal:  Thorax       Date:  1993-11       Impact factor: 9.139

3.  Neoplastic pericardial disease: Old and current strategies for diagnosis and management.

Authors:  Chiara Lestuzzi
Journal:  World J Cardiol       Date:  2010-09-26

4.  Intralymphatic delivery of platinum-based chemotherapeutics is possible: an experimental study.

Authors:  Murat Zor; Ibrahim Yildirim; Seref Basal; Halil Yaman; Mustafa Ozturk; Cem Hasan Irkilata; Serdar Goktas; Murat Dayanc
Journal:  J Cancer Res Clin Oncol       Date:  2012-05-26       Impact factor: 4.553

5.  Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade.

Authors:  Takatsugu Oida; Kenji Mimatsu; Hiso Kano; Atsushi Kawasaki; Youichi Kuboi; Nobutada Fukino; Sadao Amano
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

6.  Intrapericardial cisplatin for the management of patients with large malignant pericardial effusion.

Authors:  W Tomkowski; M Szturmowicz; A Fijalkowska; S Filipecki; E Figura-Chojak
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 7.  Common emergencies in cancer medicine: cardiovascular and neurologic syndromes.

Authors:  C R Thomas; E A Edmondson
Journal:  J Natl Med Assoc       Date:  1991-11       Impact factor: 1.798

8.  Ultrasound guided pericardial drainage and intrapericardial instillation of mitomycin C for malignant pericardial effusion.

Authors:  L N Lee; P C Yang; D B Chang; C J Yu; J C Ko; Y S Liaw; R G Wu; K T Luh
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

9.  Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer.

Authors:  T Moriya; Y Takiguchi; H Tabeta; R Watanabe; H Kimura; K Nagao; T Kuriyama
Journal:  Br J Cancer       Date:  2000-10       Impact factor: 7.640

10.  Hypoxia differently modulates the release of mitochondrial and nuclear DNA.

Authors:  Amaelle Otandault; Jean-Daniel Abraham; Zahra Al Amir Dache; Abdelnaby Khalyfa; Isabelle Jariel-Encontre; Thierry Forné; Corinne Prévostel; Salem Chouaib; David Gozal; Alain R Thierry
Journal:  Br J Cancer       Date:  2020-01-13       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.